Elevated troponin I predicts clinical events in patients admitted with acute heart failure: Insights from the RITZ-4 trial  by unknown
142A ABSTRACTS - Cardiac Function and Heart Failure 
1 P-year all-cause and cardiac mortalities in patients with left ventricular systolic dysfunc- 
tion, including those without overt heart failure at baseline. 
JACC March 19,2003 
The data from this retrospective analysis of RITZ-4 suggest that an elevated cTn I on 
admission in patients with acute ischemic HF is associated with a higher short-term risk 
of death, worsening heart failure, or recurrent or new ischemia or Ml. These results sug- 
gest that ischemia and myocyte necrosis is important prognostically in the setting of 
acute HF and is likely a significant contributor to worse outcomes. cTn may be a useful 
prognostic marker or risk stratification tool in future clinical HF trials and potentially clini- 
cal practice, particularly in patients with underlying ischemic heart disease. 
1013-74 Predictors of Mortality After Hospitalization for 
Decompensated Heart Failure 
Doron Aronson. Darlene P. Horton. Andrew J. Burger, Rambam Medical Center, Halfa, 
Israel, Beth Israel Deaconess Medical Center, Boston, MA 
Background: Hospitalization for decompensated heart failure (HF) is associated with a 
high mortality after discharge. Despite the large number of hospital admissions for HF, lit- 
tle data are available on the outcome of such patients after hospital discharge. 
Methods: The effect of baseline clinical parameters on mortality was evaluated in 560 
patients (mean age 63 * 14 years, 377 male) with a previous diagnosis of HF (96% with 
NYHA class Ill or IV) who ware admitted for decompensated HF. 
Results: During a mean follow-up of 343 f 185 days, 177 patients (32%) died. A Cox 
proportional-hazards model, adjusted for age, gender, diabetes, primary etiology of HF 
stratified as ischemic or nonischemic, sodium, blood urea nitrogen (BUN), creatinine, and 
medical therapy (ACE inhibitors, P-blockers, digoxin, and amiodarone) identified the fol- 
lowing variables as predictors of increased mortality: age > 65y (RR = 1.5, 95% Cl 1.1. 
2.1, p = O.Ol), ischemic HF (RR = 1.8, 95% Cl 1.3-2.6, p = O.OOl), sodium 2 135 (RR = 
1.8, 95% Cl 1.3-2.5, p = 0.004) and elevated BUN. The risk of death increased continu- 
ously with each quartile of BUN (Figure), with a 3-fold increase in mortality in patients in 
the upper compared to the lower quartile of BUN (95% Cl 1 7-5.3, p = 0.0003). Creatinine 
was not a predictor of mortality after adjustment for other covariates. 
Conclusion: Simple clinical variables provide useful prognostic information in patients 
with decompensated HF. BUN appears to be the most powerful predictor of post-dis- 
charge outcome. 
1013-72 Limited Diagnostic Accuracy of B-Type Natriuretic 
Peptide to Predict Cardiac Filling Pressures in Patients 
Treated for Severe Congestive Heart Failure 
William A. Parsona% Julia Potter, Gus Koerbin. Andrew J. Galbraith, The Prince 
Charles Hospital, Brisbane. Australia 
Background: Measurement of plasma B- type natriuretic peptide (BNP) is a novel and 
accurate non-invasive method of diagnosing congestive heart failure (CHF) in patients 
presenting with dyspnoea. In view of the relationship between BNP and elevated cardiac 
filling pressures it has been suggested that BNP may be used to guide therapy in 
patients with established CHF. However the accuracy of BNP for predicting filling pres- 
sures in patients receiving conventional medical treatment for severe CHF has not been 
well documented. We studied this relationship in a large cohort of patients. 
Method: We sampled blood for measurement of BNP in 76 patients with severe CHF 
immediately prior to right heart cathetedsation. Plasma BNP was measured using the 
commercially available Triage BNP@ fluorescent immunoassay (Biosite Diagnostics, 
Velozy, France). Diagnostic accuracy and the predictive value of BNP for a pulmonary 
capillary wedge pressure (PCWP) of >15mmHg was calculated in the usual way to deter- 
mine the most accurate cut off value for BNP. 
Results: Patients had severe CHF indicated by a mean PCWP of 20+12mmHg and car- 
diac index of 2.4*0.7lJmin/n?. despite the fact that >r30% were on treatment inhlbitmg the 
renin-angiotansin system and 36% ware taking a beta blocker. A BNP of >lOOpglml gave 
a sensitivity of 56% and a specificity of 91% for PCWP >15mmHg. The negative predic- 
tive value of this level for a PCWP, 15mmHg was 64% and the diagnostic accuracy 72%. 
Conclusion: This is the largest study validating a commercially available BNP assay 
against invasively measured hemodynamics in a cohort of patients with severe CHF 
despite conventional treatment. In this cohort the diagnostic accuracy of BNP for prog- 
nostically important elevation of PCWP is limited. Relying on BNP alone to guide therapy 
would lead to underestimation of PCWP in over a third of patients. It is possible that the 
relationship between PCWP and BNP is confounded by conventional CHF treatment or 
that the relationship simply breaks down at the severe extreme of the disease spectrum. 
Our results suggest that there may be limitations to the use of BNP guided therapy III 
patients with CHF. 
1013-73 Elevated Troponin I Predicts Clinical Events in Patients 
Admitted With Acute Heart Failure: Insights From the 
RITZ-4 Trial 
Christopher M. O’Connor, Wendy A. Gattis, Vie Hasselblad, Isaac Kobrin, Kirkwood F. 
Adams, Jr., Mihai Gheorghiade, Duke Clinical Research Institute. Durham, NC, Actelion. 
Ltd., Basel, Switzerland 
Background: Cardiac troponins (cTn) are important prognostic indicators in patients with 
acute coronary syndrome (ACS) and may be useful for risk stratifying patients with heart 
failure (HF). Few data are available to describe patients with ACS in the setting of acute 
HF. The relationship of cTn to clinical outcomes has not been described in this patient 
population. The purpose of this analysis was to characterze the relationship of cTn I and 
clinical outcomes among patients with acute ischemic HF enrolled Into the RITZ-4 study. 
Methods: RITZ-4 was a multi-center, randomized, double-blind, placebo controlled trial of 
the endothelin receptor antagonist tezosentan in patients admitted with ACS and acute 
HF. 193 patients were enrolled in this study. ACS was defined by ECG changes, or CK, 
CKMB, cTn T. or cTn I. The primary endpoint of RITZ-4 was the combined incidence of 
death, worsening HF, or recurrent or new ischemia or MI, within 72 hours after random- 
ization. Patients with baseline cTn I values were included in this analysis. Results: 133 
patients had values for cTn I at admission in RITZ-4 and were included in this analysis. 
The median (2d”. 75’7 age of this population was 68.5 (56, 76) years. The population 
was 51% men. and 72% were Caucasian. Forty-two patients had cTn I < 1.0 nglmL and 
91 patients had cTn I Z 1 .O ng/mL. Patients with cTn I _> 1 .O ng/mL had a higher lrw- 
dence of the composite primary endpoint as compared to patients with cTn I < 1 .O ng/mL, 
28.6% vs 23.8%, respectively, odds ratio 1.15, 95% Cl 1.01-1.32, p=O.O4. 
Conclusions: 
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1013-75 Uncovering Heart Failure in Patients With 
Bronchospasm: Rationale for the Early Use of B-Type 
Natriuretic Peptide in the Emergency Department 
PeterA. McCullough, Torbjorn Omland, Catherine W. Knudsen, Philippe Due, Richard M. 
Nowak. James McCord, Judd E. Hollander, Marie-Claude Aumont. Philippe Gabriel Steg. 
Arne Westheim, Alan B. Storrow, William T. Abraham, Sumant Lamba, Alan H. Wu, Alan 
S. Maisel, BNP Multinational Study Investigators, William Beaumont Hospital, Royal 
Oak, MI. University of California, San Diego School of Medicine, Veterans Affairs Medical 
Center, San Diego, CA 
Introduction: Plasma B-type natriuretic peptide (BNP) determination can be used to reli- 
ably identify patients with acute congestive heart failure (CHF) in patients presenting in 
the emergency department (ED) with acute dyspnea. Impaired left ventricular (LV) sys- 
tolic and diastolic function as well as increased left ventricular (LV) mass are asssociated 
with increased circulating BNP levels. Heart failure, asthma, chronic obstructive pulmo- 
nary disease (COPD). and other bronchospastic disorders, are syndromes where dysp- 
nea and wheezing are overlapping signs, and hence, these syndromes are often diflicult 
to differentiate. 
Methods The BNP Multinational Study was a seven-center prospective study of 1586 
patients presenting to the ED with acute dyspnea and had blinded BNP levels measured 
wth a rapid, point-of-care device on arrival. The reference standard for CHF was adjudi- 
cated by two independent cardiologists, also blinded to BNP results, who reviewed all 
clinical data and standardized CHF scores. 
Results A total of 417 subjects (mean age 62.2 years, 64.4% male) had a history of 
asthma or COPD without a history of CHF. Of these, 871417 (20.9%, 95% Cl 17.1. 
25.1%) were found to have CHF as the final adjudicated dlagnosls. The ED physicians 
identified 32/87 (36.8%) as having CHF. The mean BNP values ware 587.0 and 108.8 
pglml for those with and without CHF, p < 0.0001. If BNP would have been added to clin- 
ical judgement, at a cutpomt of 100 pglml. 83187 (95.4%) of CHF subjects would have 
been correctly diagnosed. In the 87 subjects who were found to have CHF, 39.0, 22.2, 
and 54.8% were taking angiotensin converting enzyme mhlbitors (ACEI), beta-blockers 
(BB). and diuretics on a chronic basis, respectively. 
Conclusion: The yield of adding routine BNP testing in patients with a history of asthma 
